Dr. Keywood is a physician with 20 years experience in the pharmaceutical industry, running European and US pre- and post-registration clinical development programs across a broad range of therapeutic areas, as well as medical marketing and pharmacovigilance activities. She has been with Addex since its inception, initially as consultant, then formally joining in 2004, overseeing Addex’s clinical development, which includes advancing internally discovered allosteric modulator products into Phase IIb clinical testing. Dr. Keywood, acting as a consultant, served from 2001 to 2003 as medical director for Axovan, a Swiss biotech company that was acquired by Actelion in 2003. From 1996 to 2001 she was medical director at CNS company Vernalis, where she helped bring a new migraine drug, Frova frovatriptan, to the market. From 1991 to 1996 she was medical director of the European subsidiary of US biotechnology company Gensia. Dr Keywood is a cardiologist who completed her post-graduate training at St Thomas’ Hospital, London.